Evogene Schedules Second Quarter 2025 Financial Results Release
Evogene (NASDAQ: EVGN), a computational biology company focused on life-science product discovery and development, has scheduled its Q2 2025 financial results release for Tuesday, August 19, 2025. The company will host a conference call to discuss the results at 9:00 AM ET (4:00 PM Israel time).
Interested participants must register in advance through the company's dedicated conference link. A recording of the conference will be made available on Evogene's website following the event.
Evogene (NASDAQ: EVGN), un'azienda di biologia computazionale specializzata nella scoperta e nello sviluppo di prodotti per le scienze della vita, ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per marted矛 19 agosto 2025. La societ脿 terr脿 una conference call per discutere i risultati alle 9:00 AM ET (16:00 ora di Israele).
I partecipanti interessati devono registrarsi in anticipo tramite il link dedicato fornito dall'azienda. Una registrazione della conferenza sar脿 disponibile sul sito web di Evogene dopo l'evento.
Evogene (NASDAQ: EVGN), una empresa de biolog铆a computacional enfocada en el descubrimiento y desarrollo de productos para ciencias de la vida, ha programado la publicaci贸n de sus resultados financieros del segundo trimestre de 2025 para el martes 19 de agosto de 2025. La compa帽铆a realizar谩 una llamada conferencia para discutir los resultados a las 9:00 AM ET (4:00 PM hora de Israel).
Los interesados deben registrarse con anticipaci贸n a trav茅s del enlace dedicado de la empresa. Una grabaci贸n de la conferencia estar谩 disponible en el sitio web de Evogene despu茅s del evento.
Evogene (NASDAQ: EVGN)電� 靸濍獏瓿柬暀 鞝滍拡 氚滉荡 氚� 臧滊皽鞐� 欷戩爯鞚� 霊� 旎错摠韯� 靸濍頃� 須岇偓搿�, 2025雲� 8鞗� 19鞚� 頇旍殧鞚检棎 2025雲� 2攵勱赴 鞛 瓴瓣臣 氚滍憸毳� 鞓堨爼頃橁碃 鞛堨姷雼堧嫟. 須岇偓電� 霃欕秬 響滌鞁� 鞓れ爠 9鞁�(鞚挫姢霛检棙 鞁滉皠 鞓ろ泟 4鞁�)鞐� 瓴瓣臣毳� 雲检潣頃橁赴 鞙勴暅 旎嵓霟办姢 旖滌潉 臧滌禍頃� 鞓堨爼鞛呺媹雼�.
彀胳劃鞚� 鞗愴晿鞁滊姅 攵勲摛鞚� 須岇偓鞚� 鞝勳毄 旎嵓霟办姢 毵來伂毳� 韱淀暣 靷爠 霌彪頃挫暭 頃╇媹雼�. 旎嵓霟办姢 雲轨潓氤胳潃 頄夓偓 頉� Evogene 鞗轨偓鞚错姼鞐愳劀 鞝滉车霅� 鞓堨爼鞛呺媹雼�.
Evogene (NASDAQ : EVGN), une entreprise de biologie computationnelle sp茅cialis茅e dans la d茅couverte et le d茅veloppement de produits en sciences de la vie, a programm茅 la publication de ses r茅sultats financiers du deuxi猫me trimestre 2025 pour le mardi 19 ao没t 2025. La soci茅t茅 tiendra une conf茅rence t茅l茅phonique pour discuter des r茅sultats 脿 9h00 ET (16h00 heure d鈥橧sra毛l).
Les participants int茅ress茅s doivent s鈥檌nscrire 脿 l鈥檃vance via le lien d茅di茅 fourni par l鈥檈ntreprise. Un enregistrement de la conf茅rence sera disponible sur le site web d鈥橢vogene apr猫s l鈥櫭﹙茅nement.
Evogene (NASDAQ: EVGN), ein Unternehmen f眉r computergest眉tzte Biologie mit Schwerpunkt auf der Entdeckung und Entwicklung von Produkten im Bereich der Lebenswissenschaften, hat die Ver枚ffentlichung der Finanzergebnisse f眉r das 2. Quartal 2025 am Dienstag, den 19. August 2025 angek眉ndigt. Das Unternehmen wird eine Telefonkonferenz zur Besprechung der Ergebnisse um 9:00 Uhr ET (16:00 Uhr Israel-Zeit) abhalten.
Interessierte Teilnehmer m眉ssen sich im Voraus 眉ber den speziellen Konferenzlink des Unternehmens registrieren. Eine Aufzeichnung der Telefonkonferenz wird nach der Veranstaltung auf der Evogene-Website verf眉gbar sein.
- None.
- None.
Zoom conference call scheduled for August 19, 2025, 9:00 AM ET
REHOVOT,
听
Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
To attend the conference, please register in advance:
The entire conference will be available online on the company's website a few days after.
About Evogene:
Evogene Ltd. (Nasdaq, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence,听aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.
Evogene established three unique tech-engines - MicroBoost听AI,听ChemPass AI听and听GeneRator AI. Each tech-engine听is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its subsidiaries,听including:
- Biomica Ltd.听()听- developing and advancing novel microbiome-based therapeutics to treat human disorders powered by听MicroBoost AI;
- Lavie Bio Ltd.听() - developing and commercially advancing, microbiome-based ag-biologicals powered by听MicroBoost AI;
- AgPlenus Ltd. () - developing next-generation ag chemicals for effective and sustainable crop protection powered by听ChemPass AI;
- Casterra Ag Ltd.听() - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by听GeneRator AI.
For more information, please visit: .
Contact:
[email protected]
Tel: +972-8-9311901
Logo: https://mma.prnewswire.com/media/1947468/4576969/Evogene_Logo.jpg
View original content:
SOURCE Evogene
FAQ
When will Evogene (EVGN) release its Q2 2025 financial results?
What time is Evogene's Q2 2025 earnings conference call?
How can investors join Evogene's Q2 2025 earnings call?
Where can I find a replay of Evogene's Q2 2025 earnings call?
